An experimental study of telomerase reverse transcriptase (hTERT) DNAzyme on growth of A549/DDP cells.
- Author:
Bingxiang YU
1
;
Jie ZHU
;
Youning LIU
;
Xiaofei ZHENG
Author Information
- Publication Type:Journal Article
- From: Chinese Journal of Lung Cancer 2006;9(5):405-408
- CountryChina
- Language:Chinese
-
Abstract:
BACKGROUNDTelomerase expresses in many cancers and may contribute to drug-resistance. The aim of this study is to observe the effect of telomerase reverse transcriptase (hTERT) DNAzyme on growth of A549/DDP cells and to explore the possibility of telomerase as a new target in treatment of drug resistance for lung cancer.
METHODSAn hTERT DNAzyme was composed. Telomerase activity was measured by telomeric repeat amplification protocol (TRAP) modified from Kim's method. MTT was used to show the influence of hTERT DNAzyme and cisplatin on A549/DDP cells.
RESULTSThe telomerase activity of A549/DDP cells was down-regulated by hTERT DNAzyme in a dose-dependent manner. The growth inhibition rate of A549/DDP cells was 32.9% by hTERT DNAzyme of 0.25μmol/L, and 60.5% by hTERT DNAzyme combined with 3mg/L cisplatin. The CDI of hTERT DNAzyme and cisplatin was 0.9.
CONCLUSIONShTERT DNAzyme can inhibit the growth of A549/DDP cells and has a synergistic effect with cisplatin. It is suggested that telomerase may be a new target in treatment of drug-resistant lung cancer cells.